A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Dec 2019
Price : $35 *
At a glance
- Drugs Glasdegib (Primary)
- Indications Graft-versus-host disease; Transplant rejection
- Focus Adverse reactions
- 16 Dec 2019 Planned End Date changed from 9 Jan 2022 to 9 Jan 2023.
- 16 Dec 2019 Planned primary completion date changed from 9 Jan 2022 to 9 Jan 2023.
- 14 Oct 2019 Planned number of patients changed from 24 to 21.